Pharma Research & Development Analysis: CPhI Annual Report

The Research and Development market has seen the greatest changes over the last 10 years within the industry. With big pharma wrestling to adapt a formerly successful model that each year is producing decreased levels of output, we are now amidst the middle of the cycle with a move away from investing in single large-scale R&D sites to diversifying interests across geographic regions, technologies and partnering firms.

This approach is leading itself to increased open innovation, out-licencing and in-licencing of technology, and outsourcing models that drive down development costs and even partnering and profit sharing arrangements.

By decentralizing the industry away from big pharma and downsizing into a greater number of smaller and more nimble biotech, CRO and discovery and development companies, pharma has vastly increased flexibility and the ability to switch between innovative targets.

The downsize of this approach has obviously been that it has decentralised regulation and increased the number of different methodologies used- meaning that many projects have a unique set of challenges and a greater degree of variants between timelines.

This model, however, has matured over the past couple of years and we are now seeing a solution that enables increased innovative output from the R&D industry, whilst maintaining a more standardised approach to R&D and, crucially, approaches to measure effectiveness and ROI.

This CPhI Pharma Insights Report examines the current trends in evaluation, adoption and partnering solutions that have been implemented across the industry to drive greater innovations and cost efficiencies.